James C. Yao

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

Arvind Dasari, Chan Shen, Daniel M. Halperin et al. · JAMA Oncology · 2017 · 3.5K citations · Full text

Medicine, Oncology, Surgery +17

Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors

Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin et al. · New England Journal of Medicine · 2017 · 3.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

James C. Yao, Manisha H. Shah, Tetsuhide Ito et al. · New England Journal of Medicine · 2011 · 2.8K citations · Full text

Medicine, Oncology, Surgery +12

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

James C. Yao, Nicola Fazio, Simron Singh et al. · The Lancet · 2015 · 1.3K citations

Medicine, Oncology, Surgery +12

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

Marianne Pavel, John D. Hainsworth, Éric Baudin et al. · The Lancet · 2011 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +16